Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.071 AUD | -1.39% | -4.05% | +2.90% |
Apr. 17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
Apr. 17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+2.90% | 47.96M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism